|
注册号: Registration number: |
ChiCTR2500102739 |
|
最近更新日期: Date of Last Refreshed on: |
2025-05-19 17:14:56 |
|
注册时间: Date of Registration: |
2025-05-19 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
细胞因子在神经病理性疼痛发病过程中的作用的临床观察和分子机制研究 |
|
Public title: |
Clinical observations and molecular mechanisms of the role of cytokines in the pathogenesis of neuropathic pain |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
细胞因子在神经病理性疼痛发病过程中的作用的临床观察和分子机制研究 |
|
Scientific title: |
Clinical observations and molecular mechanisms of the role of cytokines in the pathogenesis of neuropathic pain |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李丽旋 |
研究负责人: |
蒋昌宇 |
|
Applicant: |
Li Lixuan |
Study leader: |
Jiang Changyu |
|
申请注册联系人电话: Applicant telephone: |
+86 135 3719 5494 |
研究负责人电话:
Study leader's |
+86 188 1906 6591 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
373289182@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
jiang-changyu@hotmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国广东省深圳市南山区南头街道桃园路89号 |
研究负责人通讯地址: |
中国广东省深圳市南山区南头街道桃园路89号 |
|
Applicant address: |
89 Taoyuan Road, Nanshan region, Shenzhen, Guangdong, China |
Study leader's address: |
89 Taoyuan Road, Nanshan region, Shenzhen, Guangdong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
华中科技大学协和深圳医院 |
||
|
Applicant's institution: |
Huazhong University of Science and Technology Union Medical College Shenzhen Hospital |
||
|
研究负责人所在单位: |
华中科技大学协和深圳医院 |
||
|
Affiliation of the Leader: |
Huazhong University of Science and Technology Union Medical College Shenzhen Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
科研伦审[ky-2023-080302]号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
华中科技大学协和深圳医院科研伦理委员会 |
||
|
Name of the ethic committee: |
Research Ethics Committee of Huazhong University of Science and Technology Union Medical College Shenzhen Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-08-25 00:00:00 | ||
|
伦理委员会联系人: |
黄晓佳 |
||
|
Contact Name of the ethic committee: |
Huang Xiaojia |
||
|
伦理委员会联系地址: |
广东省深圳市南山区桃园路89号 |
||
|
Contact Address of the ethic committee: |
89 Taoyuan Road, Nanshan District, Shenzhen, Guangdong |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 132 6667 7988 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
华中科技大学协和深圳医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Huazhong University of Science and Technology Union Medical College Shenzhen Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省深圳市南山区桃园路89号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
89 Taoyuan Road, Nanshan District, Shenzhen, Guangdong |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
深圳市南山区卫生系统科技重大专项项目NSZD2023017 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shenzhen Nanshan District Health System Science and Technology Major Special Project NSZD2023017 |
||||||||||||||||||||||
|
研究疾病: |
带状疱疹神经痛 |
||||||||||||||||||||||
|
Target disease: |
Herpes zoster neuralgia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
本项目旨在通过检测参与者的血液信息鉴定在带状疱疹后遗神经痛(PHN)发病过程中,起到决定性作用的细胞因子,探究用于判断PHN发生的参考指标,为带状疱疹临床诊疗提供参考,具有极大的实用性和现实价值。 |
||||||||||||||||||||||
|
Objectives of Study: |
The aim of this project is to identify the cytokines that play a decisive role in the pathogenesis of postherpetic neuralgia (PHN) by testing the blood information of the participants, and to explore the reference indexes used to determine the occurrence of PHN, so as to provide a reference for the clinical diagnosis and treatment of herpes zoster, which is of great practicality and realistic value. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
患者排除标准 1.涉及多个节段; 2.患有严重的心血管疾病、肺部疾病或者肝肾功能异常; 3.其他疾病引起的剧烈疼痛; 4.酗酒和药物滥用者; 5.患有精神障碍且不能取得知情同意的。 健康受试者排除标准 1.无行为能力者; 2.患有严重的心血管疾病、肺部疾病或者肝肾功能异常; 3.存在免疫抑制性或自身免疫性疾病者; 4.存在酗酒和药物滥用者; 5.有精神病史者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Patient Exclusion Criteria 1. Multiple segments are involved; 2. Suffering from severe cardiovascular disease, lung disease or abnormal liver and kidney function; 3. Severe pain caused by other diseases; 4. Alcoholics and drug abusers; 5. Those who have a mental disorder and cannot obtain informed consent. Exclusion criteria for healthy subjects 1. Incapacitated; 2. Suffering from severe cardiovascular disease, lung disease or abnormal liver and kidney function; 3. Those with immunosuppressive or autoimmune diseases; 4. Presence of alcohol and drug abuse; 5. Those with a history of mental illness. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-06-12 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-09-11 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
ResMan,论文发表后一年内, http://www.medresman.org.cn/login.aspx。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan, within one year of publication, http://www.medresman.org.cn/login.aspx. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
1.所有纳入样本(含脱落样本)人口学资料:含年龄、性别、籍贯(方言)、病史、教育程度;2.临床数据(含原始数据):所有纳入样本(含脱落样本)的VAS和NRS疼痛评分表、STAI-Form Y状态焦虑问卷、PANAS正性负性情绪量表以及Beck抑郁自评量表;TSK17运动恐惧症量表,WOMAC和KOOS关节功能评分量表;患者生命体征(心率、呼吸频率、血压、血氧饱和度);其他后续可能加入的看临床数据。3. 临床统计数据及临床报告。4. 电子采集和管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1. Demographic data of all included samples (including shedding samples): including age, gender, place of origin (dialect), medical history, and education level; 2. clinical data (including raw data): the VAS and NRS pain rating scales, the STAI-Form Y State Anxiety Questionnaire, the PANAS Positive and Negative Emotions Scale, and the Beck Self-Rating Scale of Depression for all included samples (including shedding samples);TSK17 Kinesiophobia Scale, WOMAC and KOOS Joint Function Rating Scale; patient's vital signs (heart rate, respiratory rate, blood pressure, oxygen saturation); and other clinical data that may be added subsequently.3. Clinical statistical data and clinical reports.4. Electronic collection and management. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |